Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

OTHER(9)
DRUG(3)
MIXED(2)
Data collection
1 trial
university-hospital-basel-switzerland
FLU or CZO as continuous infusion
1 trial
phase_2
university-hospital-basel-switzerland
Data collection: Amikacin concentration
1 trial
university-hospital-basel-switzerland
Sub-study quantitative measurement of Torque Teno virus
1 trial
university-hospital-basel-switzerland
Data collection: blood samples (analysed for EBV serology, auto-antibody-testing/biobanking, RNA expression analyses, procalcitonin)
1 trial
university-hospital-basel-switzerland
Blood samples for the measurement of the concentration of cefazolin
1 trial
university-hospital-basel-switzerland
S. aureus culture isolate
1 trial
university-hospital-basel-switzerland
Data collection: Patient reported outcome (Fatigue questionnaires)
1 trial
university-hospital-basel-switzerland

+6 more interventions

14 unique interventions3 categories

Analytics

Trial Phases

Phase 22

Trial Status

Completed3
Recruiting2
Terminated1

Role Distribution

Principal Investigator6
PI Rate100%

Activity Timeline

Clinical Trials (6)

NCT05655091Phase 2Recruiting
Target Attainment of Continuous Infusion Flucloxacillin and Cefazolin Coupled With TDM vs. Standard of Care Treatment in Patients With Complicated S. Aureus Infection
Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI)
PrincipalinvestigatorStart date: 2023-10-26
NCT05689450Completed
Probability of Optimal Target Attainment of Amikacin in Patients With Febrile Neutropenia During Treatment for a Hematological Disorder
Febrile Neutropenia (FN)
PrincipalinvestigatorStart date: 2022-12-21
NCT05300425Completed
Seroprevalence of Leptospirosis in Val Müstair, Switzerland
Hepatitis E Virus InfectionLeptospirosisTularemia
PrincipalinvestigatorStart date: 2022-03-03
NCT05127980Recruiting
Occurrence of Antibodies Cross-reacting With Autoantigens in Primary EBV Infection
Epstein-Barr Virus (EBV) Infection
PrincipalinvestigatorStart date: 2021-10-15
NCT04414631Phase 2Terminated
Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
Coronavirus Infections
PrincipalinvestigatorStart date: 2020-08-06
NCT04503252Completed
Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus
Staphylococcus Aureus Infection
PrincipalinvestigatorStart date: 2020-01-14

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Francis COUTURAUD

CHU Brest

Related
1 trials

Shared therapeutic areas:

Coronavirus Infections
Similarity Score4%

Ashika Ahmed, MD

Bellerophon Therapeutics

Related
11 trials

Shared therapeutic areas:

Coronavirus Infections
Similarity Score4%

Marc ANDRONIKOF

AP-HP Hôpital Béclère

Related
1 trials

Shared therapeutic areas:

Coronavirus Infections
Similarity Score4%

Henri Hani KARAM

CHU Limoges

Related
1 trials

Shared therapeutic areas:

Coronavirus Infections
Similarity Score4%

Sabine Hazan, MD

ProgenaBiome

Related
41 trials

Shared therapeutic areas:

Coronavirus Infections
Similarity Score4%

Laure ABENSUR VUILLAUME

CHRU Metz-Thionville

Related
1 trials

Shared therapeutic areas:

Coronavirus Infections
Similarity Score4%

Marc NOIZET

CHRU Mulhouse

Related
1 trials

Shared therapeutic areas:

Coronavirus Infections
Similarity Score4%

Andrea PENALOZA

Cliniques Universitaires St Luc (Bruxelles)

Related
1 trials

Shared therapeutic areas:

Coronavirus Infections
Similarity Score4%

Frédéric BALEN

University Hospital, Toulouse

Related
1 trials

Shared therapeutic areas:

Coronavirus Infections
Similarity Score4%

Yann-Erick CLAESSENS

CH Princesse Grace de Monaco

Related
1 trials

Shared therapeutic areas:

Coronavirus Infections
Similarity Score4%

Publications (0)

No publications found for this investigator.

Clinical Trials (6)

Showing 6 of 6 trials

NCT05655091Phase 2PrincipalInvestigator

Target Attainment of Continuous Infusion Flucloxacillin and Cefazolin Coupled With TDM vs. Standard of Care Treatment in Patients With Complicated S. Aureus Infection

Complicated Staphylococcus Aureus (S. Aureus) Infections (CSAI)
Recruiting
NCT05689450PrincipalInvestigator

Probability of Optimal Target Attainment of Amikacin in Patients With Febrile Neutropenia During Treatment for a Hematological Disorder

Febrile Neutropenia (FN)
Completed
NCT05300425PrincipalInvestigator

Seroprevalence of Leptospirosis in Val Müstair, Switzerland

Hepatitis E Virus InfectionLeptospirosisTularemia
Completed
NCT05127980PrincipalInvestigator

Occurrence of Antibodies Cross-reacting With Autoantigens in Primary EBV Infection

Epstein-Barr Virus (EBV) Infection
Recruiting
NCT04414631Phase 2PrincipalInvestigator

Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19

Coronavirus Infections
Terminated
NCT04503252PrincipalInvestigator

Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus

Staphylococcus Aureus Infection
Completed

All 6 trials loaded